Featured Editorial
3 Crucial Discussions From The Biosimilar Medicines Conference
 
By Anna Rose Welch, editor, Biosimilar Development

After four years of writing about biosimilars, I can finally say I attended the annual Biosimilar Medicines Conference organized by Medicines for Europe. This conference was valuable, not only to see which efforts have been successful in Europe, but also to get a closer look at what hurdles remain.

Will PBM Transparency Help Biosimilar Utilization?
 
By Ronald W. Lanton III, Frier Levitt Government Affairs, LLC

The current dearth of transparency, as well as a lack of consistent regulatory state and federal oversight, has greatly contributed to the increase in prescription drug costs. This leads to the question of whether increased pharmacy benefit manager (PBM) transparency — and the efforts being developed to introduce greater pricing transparency — will positively impact biosimilars.

How Can Manufacturers, Oncologists Prepare For The Oncology Biosimilar Boom?
 
By Anna Rose Welch, editor, Biosimilar Development

A few months ago, I read a fabulous Q&A featuring oncologist Gary Lyman. I reached out to Lyman myself to learn more about the dynamics playing out in the hospital setting for biosimilars, as well as how physicians and drug makers can foster a greater understanding of biosimilar medicines.

Industry Insights
Fluorescent Western Blotting: Helpful Tips For Optimizing Your Protocol
Article | By Gunjan Choudhary, Poulomi Acharya, and Raymond Miller, Bio-Rad Laboratories, Inc.

Fluorescent western blotting is a technique where fluorescently tagged detection antibodies help directly determine the level of protein expression. It is a method that is becoming increasingly popular due to recent advances in digital imaging technology and fluorescent western blotting reagents. Not quite sure about this technique? Read about the reasons to start fluorescent western blotting.

Western Blot Detection: Is Film Or A Digital CCD Imager Better?
Article | GE Healthcare Life Sciences

Learn the benefits and drawbacks of using film or a CCD imager to detect the bound antibody in Western blotting, also known as immunoblotting.

Sponsor
 

Have you wondered how your investments and challenges stack up compared to other biosimilars? Pharma IQ has created the "Biosimilars Investment Trends Infographic" based on insights from commercialization and market access professionals to better understand the market — download your copy of the infographic here.
Download now to discover:

  • Reasons why companies aren't currently outsourcing
  • Biggest factors in choosing a new solutions provider
  • Main challenges in biosimilar commercialization currently
Solutions
ÄKTA Readyflux Single-Use Filtration System
GE Healthcare Life Sciences
Connect With Biosimilar Development:
      Twitter